Fundies.
English

Segment disclosures

Company overview

Supernus Pharmaceuticals, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 19 retained observations 13 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=supn:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30226771000 USD2026-10-29 · 20:12:17.000ZOpen filing evidence
2026-01-01 – 2026-09-30653534000 USD2026-10-29 · 20:12:17.000ZOpen filing evidence
2026-04-01 – 2026-06-30219058000 USD20260803Open filing evidence
2026-01-01 – 2026-06-30426763000 USD20260803Open filing evidence
2026-01-01 – 2026-03-31207705000 USD20260505Open filing evidence
2025-01-01 – 2025-12-31718952000 USD20260302Open filing evidence
2025-07-01 – 2025-09-30192103000 USD2026-10-29 · 20:12:17.000ZOpen filing evidence
2025-01-01 – 2025-09-30507380000 USD2026-10-29 · 20:12:17.000ZOpen filing evidence
2025-04-01 – 2025-06-30165453000 USD20260803Open filing evidence
2025-01-01 – 2025-06-30315277000 USD20260803Open filing evidence
2025-01-01 – 2025-03-31149824000 USD20260505Open filing evidence
2024-01-01 – 2024-12-31661817000 USD20260302Open filing evidence
2024-07-01 – 2024-09-30175689000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30487658000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30168325000 USD20250805Open filing evidence
2024-01-01 – 2024-06-30311969000 USD20250805Open filing evidence
2024-01-01 – 2024-03-31143644000 USD20250506Open filing evidence
2023-01-01 – 2023-12-31607521000 USD20260302Open filing evidence
2022-01-01 – 2022-12-31667238000 USD20250225Open filing evidence